share_log

礼来(LLY.US)探索“减肥神药”Zepbound新用途 目标降低糖尿病等高风险人群发病率

Eli Lilly and Co (LLY.US) explores new uses for 'weight-loss miracle drug' Zepbound, aiming to reduce the incidence of high-risk populations such as diabetes.

Zhitong Finance ·  Oct 2 15:57

Eli Lilly and Co is exploring new uses for its weight loss drug Zepbound to reduce the incidence of diabetes in high-risk populations, even if they are not overweight.

Smart Finance APP learned that Eli Lilly and Co (LLY.US) is exploring new uses for its weight loss drug Zepbound to reduce the incidence of diabetes in high-risk populations, even if they are not overweight. The company's CEO Dave Ricks revealed that the company plans to test Zepbound as a health maintenance therapy targeting individuals with a Body Mass Index (BMI) below the overweight level. Currently, Zepbound and another weight loss candidate drug orforglipron from the company mainly target patients with a BMI of 30 and above, as well as patients with a BMI of 27 and above with other weight-related health issues.

Ricks stated that the company aims to lower the BMI threshold to 25 or lower to investigate the drug as a potential means of preventing diabetes, stroke, or vascular dementia. This strategy is particularly meaningful for certain populations with a lower BMI but higher risk of diabetes, such as Pacific Islanders.

Nevertheless, Eli Lilly and Co still considers it inappropriate to use Zepbound for cosmetic weight loss.

It is understood that Zepbound, also known as tirzepatide, is a GLP-1 class drug, with novo-nordisk a/s's semaglutide as its main competitor in the market, sold under the brands Ozempic and Wegovy.

GLP-1 class drugs have drawn attention due to their potential in weight loss and blood sugar control. In addition, several companies are actively developing weight loss drugs, including amgen (AMGN.US), pfizer (PFE.US), astrazeneca (AZN.US), roche (RHHBY.US), boehringer ingelheim, viking therapeutics (VKTX.US), altimmune (Alt.US), Zealand Pharma, and GPCRs (GPCR.US), all seeking to develop new solutions for treating obesity and related diseases.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment